MétaCan
Menu
Back to cohort
Record W4229524878 · doi:10.1016/j.juro.2012.02.659

583 A POPULATION-BASED COMPETING-RISKS ANALYSIS OF SURVIVAL AFTER NEPHRECTOMY FOR RENAL CELL CARCINOMA

2012· article· en· W4229524878 on OpenAlexaboutno aff
Marco E. Bianchi, Maxine Sun, Quoc‐Dien Trinh, Jens Hansen, Zhe Tian, Umberto Capitanio, Alberto Briganti, Shahrokh F. Shariat, Paul Perrotte, Francesco Montorsi, Pierre I. Karakiewicz

Bibliographic record

VenueThe Journal of Urology · 2012
Typearticle
Languageen
FieldMedicine
TopicRenal cell carcinoma treatment
Canadian institutionsnot available
Fundersnot available
KeywordsMedicineNephrectomyRenal cell carcinomaPopulationEpidemiologyDemographyOncologyInternal medicineKidney

Abstract

fetched live from OpenAlex

You have accessJournal of UrologyKidney Cancer: Evaluation and Staging I1 Apr 2012583 A POPULATION-BASED COMPETING-RISKS ANALYSIS OF SURVIVAL AFTER NEPHRECTOMY FOR RENAL CELL CARCINOMA Marco Bianchi, Maxine Sun, Quoc-Dien Trinh, Jens Hansen, Zhe Tian, Umberto Capitanio, Alberto Briganti, Shahrokh Shariat, Paul Perrotte, Francesco Montorsi, and Pierre Karakiewicz Marco BianchiMarco Bianchi Milan, Italy More articles by this author , Maxine SunMaxine Sun Montreal, Canada More articles by this author , Quoc-Dien TrinhQuoc-Dien Trinh Detroit, MI More articles by this author , Jens HansenJens Hansen Hamburg, Germany More articles by this author , Zhe TianZhe Tian Montreal, Canada More articles by this author , Umberto CapitanioUmberto Capitanio Milan, Italy More articles by this author , Alberto BrigantiAlberto Briganti Milan, Italy More articles by this author , Shahrokh ShariatShahrokh Shariat New York, NY More articles by this author , Paul PerrottePaul Perrotte Montreal, Canada More articles by this author , Francesco MontorsiFrancesco Montorsi Milan, Italy More articles by this author , and Pierre KarakiewiczPierre Karakiewicz Montreal, Canada More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2012.02.659AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES Competing cause of mortality has been examined in patients with localized renal cell carcinoma (RCC). However the effect of tumor grade has not been accounted for. We reassessed this topic in all RCC stages integrating tumor grade. METHODS The Surveillance, Epidemiology, and End Results (SEER) database was used to identify 42090 patients treated with NT between years 1988 and 2008. Patients were stratified in 32 strata according to age groups (≤59, 60-69, 70-79, and ≥80 years), Fuhrman grade (I-II vs. III-IV) and American Joint Committee on Cancer (AJCC) stage which resulted in a total of 32 combinations. Competing risk Poisson analyses were performed to simultaneously assess the rates of CSM and OCM at 5 years after nephrectomy. RESULTS Overall 11153 deaths occurred (27%). Of those, 5554 (50%) were due to CSM events. The risk of CSM and OCM at five years after nephrectomy is illustrated in Figure 1. Several findings were observed. First, amongst low-grade tumors, the highest CSM rates at five years were recorded in the youngest age group (≤59 years) with AJCC stage IV RCC (63%). In contrast, the highest OCM rate at five years were recorded in the oldest age group (≥80 years) with AJCC stage I RCC (33%). Not surprisingly, CSM rates increased with disease stage, while OCM rates increased with age. Second, amongst high-grade tumors, a similar trend was recorded where the highest CSM rate at five years were recorded in the youngest age group with AJCC stage IV RCC (79%), while the highest OCM rate at five years was recorded in the oldest age group with AJCC stage I RCC (44%). Finally, it is also noteworthy tumor grade was not particularly detrimental amongst patients with AJCC stage I RCC, especially in the elderly. For example, the five-year CSM rate in patients aged ≤80 years with AJCC stage I RCC was 7% for low-grade vs. 8% for high-grade disease. In contrast, for the same stage, the five-year CSM rate in patients aged ≤59 years was 2% for low-grade vs. 6% for high-grade disease. CONCLUSIONS Our study provides a valuable graphical aid for prediction of CSM, and OCM, according to patient age, disease stage and grade in patients treated with NT for RCC, and this can help clinicians to better stratify the risk-benefit ratio of NT. © 2012 by American Urological Association Education and Research, Inc.FiguresReferencesRelatedDetails Volume 187 Issue 4S April 2012 Page: e238 Advertisement Copyright & Permissions© 2012 by American Urological Association Education and Research, Inc.Metrics Author Information Marco Bianchi Milan, Italy More articles by this author Maxine Sun Montreal, Canada More articles by this author Quoc-Dien Trinh Detroit, MI More articles by this author Jens Hansen Hamburg, Germany More articles by this author Zhe Tian Montreal, Canada More articles by this author Umberto Capitanio Milan, Italy More articles by this author Alberto Briganti Milan, Italy More articles by this author Shahrokh Shariat New York, NY More articles by this author Paul Perrotte Montreal, Canada More articles by this author Francesco Montorsi Milan, Italy More articles by this author Pierre Karakiewicz Montreal, Canada More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.005
metaresearch head score (Gemma)0.012
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.009
Threshold uncertainty score0.028

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0050.012
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.004
Bibliometrics0.0010.001
Science and technology studies0.0000.000
Scholarly communication0.0010.001
Open science0.0010.001
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0070.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.037
GPT teacher head0.295
Teacher spread0.258 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2012
Admission routes1
Has abstractyes

Explore more

Same venueThe Journal of UrologySame topicRenal cell carcinoma treatmentFrench-language works237,207